Evaluation of a gene signature to predict single agent dacetuzumab (SGN-40) activity in patients with DLBCL No significant financial relationships to disclose. This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results